Table 1.
ORR (%) | VGPR/CR (%) | PFS (mo) | |
---|---|---|---|
Standard rituximab | 40 | 0-5 | 13 |
Extended rituximab | 60 | 5-10 | 16-29 |
Thalidomide rituximab | 70 | 10 | 30% |
Cyclophosphamide rituximab | 70-80 | 20-25 | 30-36 |
Nucleoside analogs rituximab | 70-90 | 20-30 | 36-62 |
Proteasome inhibitors rituximab | 80-90 | 30-40 | 42-66 |
Bendamustine rituximab | 90 | 30 | 69 |